Dr. Aaron L. Ellenbogen, DO

Dr. Ellenbogen practices at Michigan Institute for Neurological Disorders in Roseville, Michigan.

Dr. Ellenbogen's NPI, 1962472241, was assigned on January 26, 2006. Dr. Ellenbogen graduated from Michigan State University College of Osteopathic Medicine in 1998. Dr. Ellenbogen holds Michigan license 014092.

Dr. Ellenbogen's primary practice is Michigan Institute for Neurological Disorders, at 25100 Kelly Rd, Roseville, MI 48066 in Macomb County. The practice phone is (248) 553-0010.

Dr. Ellenbogen's primary practice is Michigan Institute for Neurological Disorders in Roseville, Michigan. Dr. Ellenbogen is also affiliated with Corewell Health William Beaumont University Hospital. The medical group on file is Michigan Institute for Neurological Disorders. Dmand AI also links Dr. Ellenbogen to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ellenbogen practices, 5 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Ellenbogen's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Ellenbogen is licensed in Michigan.

CMS data shows 62,292 Medicare services from Dr. Ellenbogen across 14 procedure codes in 2024, for 570 Medicare patients. Medicare paid $440,833 for them.

CMS counts 570 Medicare patients who saw Dr. Ellenbogen in 2024. The largest group is 65 to 74, with 236 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ellenbogen's median patient age at 68, with 55% women.

In 2024, Dr. Ellenbogen wrote 4,907 Medicare Part D claims for 748 patients. 81% of them were for generic drugs. CMS names the drug for 4,640 of them, across 81 drugs with 11 or more claims each, at $3,759,722 in total drug cost. In 2023, CMS named 4,624 claims across 78 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Ellenbogen for performance year 2024, reported as part of a group. Dr. Ellenbogen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ellenbogen as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 28 papers to Dr. Ellenbogen, published from 2011 to 2025. 2025 was the busiest year, with 4. The most frequent topics are Parkinson Disease, Levodopa and Antiparkinson Agents. Dr. Ellenbogen has published most often in Clin Neuropharmacol. Dr. Ellenbogen's most frequent co-authors are Robert A. Hauser, MD, Alberto J. Espay, MD and Stuart H. Isaacson, MD.

Dmand AI links Dr. Ellenbogen to 11 clinical trials, 5 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Parkinson Disease, Parkinsonian Disorders and Migraine Disorders. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Ellenbogen that name 3 trials.

CMS Open Payments shows 2,696 general payments to Dr. Ellenbogen from 72 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 62% of the total. Allergan Inc. paid the most, $603,953. It also lists 28 research payments totaling $212,634 from 2016 to 2025, naming 3 clinical trials.

Dr. Ellenbogen graduated from Michigan State University College of Osteopathic Medicine in 1998.